• Media type: E-Article
  • Title: Abstract A04: Metabolic reprogramming of MYCN amplified neuroblastoma
  • Contributor: Morrison, Monique; Khuu, Scott; Schiffman, Joshua; Cairns, Bradley; Rutter, Jared; Winge, Dennis; Speleman, Frank; Stewart, Rodney
  • imprint: American Association for Cancer Research (AACR), 2015
  • Published in: Molecular Cancer Research
  • Language: English
  • DOI: 10.1158/1557-3125.myc15-a04
  • ISSN: 1557-3125; 1541-7786
  • Keywords: Cancer Research ; Oncology ; Molecular Biology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:p>Neuroblastoma (NB) is a highly malignant embryonic tumor of neural crest origin and accounts for 15% of all cancer deaths in children. Amplification of the MYCN oncogene, which occurs in ~25% of patients, is the most reliable marker of metastatic disease and predicts poor outcome. Recent findings show MYCN reprograms NB cell metabolism to promote glycolysis and shunting of glutamate into the TCA cycle, causing dependence on increased levels of TCA intermediates, such as a-KG and succinate. Allelic loss of the short arm of chromosome 1, (1p36) is associated with the vast majority of MYCN amplified NB, and a candidate tumor suppressor gene (TSG) in this region is succinate dehydrogenase subunit B,SDHB, which encodes a core component of the succinate dehydrogenase (SDH) complex, converting succinate to fumarate. We show that MYCN-amplified NB cells, with 1p deletion, have reduced SDHB protein levels and elevated succinate levels. Thus, we are now testing a model that the combined loss of SDH activity with MYCN amplification causes dramatic accumulation of cytosolic succinate, which in turn stabilizes HIF1α to accelerate NB pathogenesis in vivo. To test this model, we have generated mutations in zebrafish sdhb to determine if 1) it is normally required for sympathetic neuron differentiation and 2) cooperates with MYCN to accelerate zebrafish NB in vivo (Zhu et. al, Cancer Cell, 2012). As HIF1a is predicted to be upregulated in SDH-deficient cells, as well as MYCN-amplified NB, we have also generated stable HIF1α transgenic zebrafish lines to directly determine if HIF1α alone is sufficient to drive NB or cooperates with MYCN to accelerate it. The results from our studies of sdhb loss and hif1α gain on peripheral sympathetic nervous system development and NB formation in vivo will be discussed as well as potential therapeutic approaches to target SDH/MYCN-dependent tumors.</jats:p> <jats:p>Citation Format: Monique Morrison, Scott Khuu, Joshua Schiffman, Bradley Cairns, Jared Rutter, Dennis Winge, Frank Speleman, Rodney Stewart. Metabolic reprogramming of MYCN amplified neuroblastoma. [abstract]. In: Proceedings of the AACR Special Conference on Myc: From Biology to Therapy; Jan 7-10, 2015; La Jolla, CA. Philadelphia (PA): AACR; Mol Cancer Res 2015;13(10 Suppl):Abstract nr A04.</jats:p>
  • Access State: Open Access